Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 11/20 | 0.66 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.58 |
| ▸ | NOS2 | P35228 | 2/20 | 0.53 |
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474816 | 1.00 | BHMT (0.66) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL474867 | 1.00 | BHMT (0.66) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL1900523 | 0.88 | BHMT (0.63) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL1900524 | 0.88 | BHMT (0.63) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL19800864 | 0.88 | BHMT (0.75) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL19800862 | 0.88 | BHMT (0.75) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL1031686 | 0.85 | BHMT (0.76) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL1031684 | 0.85 | BHMT (0.76) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL21851894 | 0.85 | BHMT (0.76) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL27791649 | 0.85 | BHMT (0.76) | BHMTBHMT2NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102448931-A | Radiolabeled fluorine derivatives of methionine | CRC FOR BIOMEDICAL IMAGING DEV LTD | 2012-05-09 | — | — | CN | disclosed |
| US-20120093726-A1 | Radiolabeled Fluorine Derivatives of Methionine | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD. (AU) | 2012-04-19 | — | — | US | disclosed |
| EP-2411360-A1 | RADIOLABELED FLUORINE DERIVATIVES OF METHIONINE | CRC For Biomedical Imaging Development Ltd (AU) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010108210-A1 | RADIOLABELED FLUORINE DERIVATIVES OF METHIONINE | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD (AU) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093726-A1 | Radiolabeled Fluorine Derivatives of Methionine | BHMT2, MGMT, AHCY | BHMT 8/4885BHMT2 1/4885NOS2 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.